New long-term data for Roche's Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO) -February 01, 2024 at 01:04 am EST

Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months...

Related Keywords

Japan ,United Kingdom ,Switzerland ,Paris ,France General ,France ,Florida ,United States ,Moorfields ,Ballymena ,America ,Sabine Borngr ,Birgit Masjost ,Kirti Pandey ,Polypoidal Choroidal Vasculopathy ,Rebekka Schnell ,Simon Goldsborough ,Ramin Tadayoni ,Bruno Eschli ,Karsten Kleine ,Loren Kalm ,Levi Garraway ,Sileia Urech ,United Kingdom National Health Service Foundation ,Genentech ,Glob Health ,Drug Administration ,Us National Institutes Of Health ,European Medicines Agency ,Head Of Global Product Development ,National Eye Institute ,Novartis ,European Union ,Bascom Palmer Eye Institute ,Roche Group ,European Society Of Retina Specialists ,Chief Medical Officer ,Global Product ,Port Delivery System ,United States Food ,Drug Administration Approved ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Eye Hospital ,Retinal Vein Occlusion ,European Society ,Retina Specialists ,Retin Eye ,Vascular Endothelial Growth Factora Inhibitor ,Patients With Polypoidal Choroidal ,Real World Study ,Product Characteristics ,Markets ,